Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market
29. Dezember 2020 16:05 ET
|
Assertio Therapeutics, Inc.
Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing Trading on Nasdaq Capital Market is expected to begin on...
Assertio Announces Restructuring Plan and Leadership Changes
15. Dezember 2020 09:00 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced a comprehensive restructuring plan designed to further...
Assertio to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
10. November 2020 16:01 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief...
Assertio Reports Third Quarter 2020 Financial Results
06. November 2020 06:00 ET
|
Assertio Therapeutics, Inc.
Reported Net Product Sales of $34.3 Million Non-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020 Non-GAAP Net Product Sales...
Assertio to Release Third Quarter 2020 Financial Results and Host Webcast on November 6, 2020
23. Oktober 2020 08:00 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its third...
Assertio to Present at Cantor Virtual Global Healthcare Conference on September 16, 2020
09. September 2020 06:02 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will...
Assertio Reports Second Quarter 2020 Financial Results
07. August 2020 06:02 ET
|
Assertio Therapeutics, Inc.
--Completed all merger and integration activities in Q2----Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2...
Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020
20. Juli 2020 06:02 ET
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020...
Assertio Therapeutics Announces First-Quarter 2020 Results
11. Mai 2020 08:00 ET
|
Assertio Therapeutics, Inc.
-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger...
Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus
20. April 2020 17:08 ET
|
Assertio Therapeutics, Inc.
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First...